| Literature DB >> 32460851 |
Cheng Zheng1,2, Shufang Zhang3, Qingqing Chen4, Li Zhong1,5, Tiancha Huang1, Xijiang Zhang2, Kai Zhang1, Hongwei Zhou6, Jiachang Cai6, Linlin Du1, Changming Wang2, Wei Cui1, Gensheng Zhang7.
Abstract
BACKGROUND: Although Staphylococcus aureus bloodstream infections (SA-BSI) are a common and important infection, polymicrobial SA-BSI are infrequently reported. The aim of this study was to investigate the clinical characteristics and risk factors of polymicrobial SA-BSI in comparison with monomicrobial SA-BSI.Entities:
Keywords: Bacteremia; Mortality; Polymicrobial Staphylococcus aureus bloodstream infections; Risk factors; Staphylococcus aureus
Mesh:
Year: 2020 PMID: 32460851 PMCID: PMC7254655 DOI: 10.1186/s13756-020-00741-6
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Flowchart of study participant enrollment. Abbreviations: SA-BSI, Staphylococcus aureus bloodstream infections
Baseline characteristics of patients with polymicrobial and monomicrobial Staphylococcus aureus bloodstream infection
| Characteristics | Total | Mono-SA-BSI | Poly-SA-BSI | |
|---|---|---|---|---|
| Age, median years (IQR) | 59.00 (45.50,68.00) | 60.00 (48,68.00) | 51.00 (40.50,69.00) | 0.06 |
| Male sex | 243 (69.6%) | 202 (68.5%) | 41 (75.9%) | 0.27 |
| Co-morbidities | ||||
| Diabetes mellitus | 70 (20.1%) | 61 (20.7%) | 9 (16.7%) | 0.50 |
| Chronic kidney disease | 31 (8.9%) | 27 (9.2%) | 4 (7.4%) | 0.88 |
| Chronic liver disease | 16 (4.6%) | 14 (4.7%) | 2 (3.7%) | 1 |
| COPD or Severe asthma | 7 (2%) | 7 (2.4%) | 0 (0%) | 0.60 |
| Chronic cardiac insufficiency | 25 (7.2%) | 22 (7.5%) | 3 (5.6%) | 0.83 |
| Solid tumor | 57 (16.3%) | 48 (16.3%) | 9 (16.7%) | 0.94 |
| Trauma | 73 (20.9%) | 54 (18.3%) | 19 (35.2%) | |
| Burn injury | 45 (12.9%) | 30 (10.2%) | 15 (27.8%) | |
| Cerebrovascular accident | 39 (11.2%) | 28 (9.5%) | 11 (20.4%) | |
| CCI, median (IQR) | 3 (1,5) | 3 (2,5) | 2 (1,4.25) | 0.08 |
| APACHE II score, median (IQR) | 12 (9,17) | 12 (8,16) | 15 (11,22) | |
| SOFA score, median (IQR) | 4 (2,6) | 3 (2,5) | 5 (2.75,10) | |
| Pitt Bacteremia Score, median (IQR) | 2 (1,4) | 1 (1,3) | 3.5 (2,6) | |
| Hospitalization ward | ||||
| ICU stay | 131 (37.5%) | 93 (31.5%) | 38 (70.4%) | |
| Previous treatment | ||||
| Parenteral nutrition | 122 (35%) | 91 (30.8%) | 31 (57.4%) | |
| Mechanical ventilation | 112 (32.1%) | 76 (25.8%) | 36 (66.7%) | |
| Antibiotic exposure | 302 (86.5%) | 251 (85.1%) | 51 (94.4%) | 0.06 |
| Surgery | 124 (35.5%) | 92 (31.2%) | 32 (59.3%) | |
| Chemotherapy/radiation | 13 (3.7%) | 13 (4.4%) | 0 (0%) | 0.23 |
| Renal replacement therapy | 43 (12.3%) | 37 (12.5%) | 6 (11.1%) | 0.77 |
| Blood transfusion | 58 (16.6%) | 37 (12.5%) | 21 (38.9%) | |
| Invasive devices | ||||
| central line catheter | 167 (47.9%) | 132 (44.7%) | 35 (64.8%) | |
| Indwelling urinary catheter | 175 (50.1%) | 132 (44.7%) | 43 (79.6%) | |
| Intraperitoneal drainage | 33 (9.5%) | 26 (8.8%) | 7 (13%) | 0.34 |
| Prior hospital stay, median days (IQR) | 8 (2,20) | 7 (1,19) | 13 (7,32.5) | |
| Nosocomial infection | 266 (76.2%) | 214 (72.5%) | 52 (96.3%) | |
| Neutropenia | 7 (2.0%) | 6 (2.0%) | 1 (1.9%) | 1 |
Abbreviations: IQR Interquartile range, COPD Chronic obstructive pulmonary disorder, CCI Charlson Comorbidity Index, SOFA Sequential organ failure assessment, APACHE Acute physiology and chronic health evaluation, ICU Intensive care unit, SA-BSI Staphylococcus aureus bloodstream infection
Comparison of biological indicators between groups of monomicrobial SA-BSI and polymicrobial SA-BSI
| Biological indicators | Total | Mono-SA-BSI | Poly-SA-BSI | |
|---|---|---|---|---|
| Temperature (°C) (IQR) | 39.0 (38.6,39.5) | 39 (38.6,39.5) | 39 (38.575,39.5) | 0.51 |
| Blood routine test | ||||
| WBC(× 109/L) (IQR) | 10.1 (6.8,14.35) | 10.3 (6.9,14.2) | 9.75 (5.5,16.65) | 0.94 |
| Hematocrit (%) (IQR) | 28.9 (24.05,33.5) | 29.2 (24.6,33.9) | 26.95 (22.6,31.2) | |
| Platelet (×109/L) (IQR) | 171 (102.5247.5) | 175 (101,248) | 145.5 (103,248) | 0.37 |
| ANC (IQR) | 8.15 (5.56,12.74) | 8.1 (5.6,12.35) | 10.545 (5.44,15.79) | 0.13 |
| Liver and kidney function | ||||
| Albumin (g/L) (mean ± S.D.) | 29.56 ± 5.66 | 30.216 ± 5.48 | 29.44 ± 5.69 | 0.36 |
| GPT (U/L) (IQR) | 31 (17,57) | 30 (17,53) | 41 (24.5,73) | |
| GOT (U/L) (IQR) | 30 (21,50) | 28 (20,47) | 36 (27.5,60.25) | |
| ALP (U/L) (IQR) | 101 (74,151) | 103 (74,150) | 99.5 (76.75,152.25) | 0.97 |
| γ-GT (U/L) (IQR) | 45 (26.0,95) | 44 (25.0,96.0) | 56.0 (27.25,89) | 0.42 |
| LDH (U/L) (IQR) | 254 (197,342) | 248 (195,321) | 343 (227.5405) | |
| TBil (μmol/L) (IQR) | 12.8 (9,20.35) | 12.7 (9,19.6) | 14.85 (9.38,26.43) | 0.26 |
| SCr (μmol/L) (IQR) | 59 (44.5,95.5) | 59 (45,96) | 65.5 (42.25,96.25) | 0.94 |
| PCT (ng/ml) (IQR) | 0.46 (0.18,1.31) | 0.46 (0.18,1.29) | 0.53 (0.22,2.08) | |
Abbreviations: SA-BSI Staphylococcus aureus bloodstream infections, IQR Interquartile range, WBC White blood count, ANC Absolute neutrophil count, GPT Glutamic-pyruvic transaminase, GOT Glutamic-oxaloacetic transaminase, ALP Alkaline phosphatase, γ-GT Gamma glutamyl transpeptidase, Lactic dehydrogenase, TBil Total bilirubin, SCr Serum creatinine, PCT Procalcitonin
Multivariable logistic regression of factors associated with polymicrobial Staphylococcus aureus bloodstream infections
| Variable | Unadjusted | Adjusted | ||
|---|---|---|---|---|
| Co-morbidities | ||||
| Trauma | 2.42 (1.29,4.56) | 0.01 | ||
| Burn injury | 3.40 (1.68,6.88) | 0.00 | 7.04 (1.71,28.94) | |
| Cerebrovascular accident | 2.44 (1.13,5.26) | 0.02 | ||
| APACHE II score | 1.08 (1.04,1.12) | 0.00 | ||
| SOFA score | 1.11 (1.04,1.18) | 0.00 | ||
| Pitt Bacteremia Score | 1.29 (1.15,1.44) | 0.00 | ||
| ICU stay | 5.16 (2.74,9.72) | 0.00 | ||
| Previous treatment | ||||
| Parenteral nutrition | 3.02 (1.67,5.47) | 0.00 | ||
| Previous surgery | 3.21 (1.77,5.83) | 0.00 | ||
| Prior Blood transfusion | 4.44 (2.32,8.47) | 0.00 | 2.72 (1.14,6.50) | |
| Central venous catheter | 2.28 (1.24,4.16) | 0.01 | ||
| Mechanical ventilation | 5.76 (3.09,10.75) | 0.00 | 3.11 (1.16,8.30) | |
| Indwelling urinary catheter | 4.83 (2.40,9.73) | 0.00 | ||
| Nosocomial infection | 9.84 (2.34,41.34) | 0.00 | ||
| Prior hospital stay | 1.02 (1.01,1.03) | 0.01 | 1.02 (1.00,1.03) | |
| Source of BSIs | ||||
| Pneumonia | 2.62 (1.44,4.78) | 0.00 | 4.22 (1.69,10.51) | |
| Central venous catheter | 0.31 (0.11,0.88) | 0.03 | ||
| MRSA | 2.36 (1.14,4.88) | 0.02 | ||
Abbreviations: CCI Charlson Comorbidity Index, SOFA Sequential organ failure assessment, APACHE Acute physiology and chronic health evaluation, ICU Intensive care unit, BSIs Bloodstream infections, MRSA Methicillin-resistant Staphylococcus aureus, OR Odds ratio, CI Confidence interval
Fig. 2Distribution of the additional organisms in polymicrobial Staphylococcus aureus bloodstream infections. Abbreviations: E. coli, Escherichia coli; A. baumannii, Acinetobacter baumannii; CNS, Coagulase-negative Staphylococcus; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; P. maltophilia, Pseudomonas maltophilia
Comparison of the microbiological characteristics with monomicrobial SA-BSI and polymicrobial SA-BSI
| Total | Mono-SA-BSI | Poly-SA-BSI | ||
|---|---|---|---|---|
| Source of BSIs | ||||
| Pneumonia | 93 (26.6%) | 69 (23.4%) | 24 (44.4%) | |
| Hospital-acquired pneumonia | 69 (74.2%) | 47 (68.1%) | 22 (91.7%) | |
| Community-acquired pneumonia | 24 (25.8%) | 22 (31.9%) | 2 (8.3%) | |
| Skin and Soft tissue infection | 86 (24.6%) | 69 (23.4%) | 16 (29.6%) | 0.33 |
| Central venous catheter | 65 (18.6%) | 61 (20.7%) | 4 (7.4%) | |
| Intra-abdominal | 42 (12%) | 34 (11.5%) | 8 (14.8%) | 0.50 |
| Primary BSI | 28 (7.7%) | 27 (9.2%) | 1 (1.9%) | 0.10 |
| Bone and joint | 14 (4.0%) | 14 (4.7%) | 0 (0%) | 0.14 |
| Endocarditis | 11 (3.2%) | 11 (3.7%) | 0 (0%) | 0.23 |
| Urinary tract infection | 9 (2.6%) | 8 (2.7%) | 1 (1.9%) | 0.58 |
| Others* | 2 (0.6%) | 2 (0.7%) | 0 (0%) | 0.71 |
| MRSA | 236 (67.6%) | 192 (65.1%) | 44 (81.5%) | |
| Delayed antibiotic therapy | 29 (8.3%) | 24 (8.1%) | 5 (9.3%) | 0.78 |
| Antibiotic resistancea | ||||
| Cefoxitin (115 vs 25)b | 114 (81.4%) | 89 (77.4%) | 25 (100%) | |
| Ciprofloxacin (237 vs 42)b | 132 (47.3%) | 96 (40.5%) | 36 (85.5%) | |
| Clindamycin (295 vs 54)b | 127 (36.4%) | 110 (37.3%) | 17 (31.5%) | 0.42 |
| Erythromycin (295 vs 54)b | 203 (58.2%) | 167 (56.6%) | 36 (66.7%) | 0.17 |
| Gentamicin (295 vs 54)b | 58 (16.6%) | 50 (16.9%) | 8 (14.8%) | 0.71 |
| Levofloxacin (261 vs 49)b | 161 (51.9%) | 118 (45.2%) | 43 (87.8%) | |
| Linezolid (293 vs 54)b | 46 (13.3%) | 37 (12.6%) | 9 (16.7%) | 0.42 |
| Moxifloxacin (287 vs 51)b | 158 (46.7%) | 117 (40.8%) | 41 (80.4%) | |
| Nitrofurantoin (255 vs 50)b | 1 (0.3%) | 1 (0.4%) | 0 (0%) | 1 |
| Oxacillin (295 vs 54)b | 236 (67.6%) | 192 (65.1%) | 44 (81.5%) | |
| Penicillin (295 vs 54)b | 333 (95.4%) | 279 (94.6%) | 54 (100%) | 0.08 |
| Quinupristin/Dalfopristin (295 vs 54)b | 44 (12.6%) | 36 (12.2%) | 8 (14.8%) | 0.60 |
| Rifampin (242 vs 43)b | 9 (3.2%) | 8 (3.3%) | 1 (2.3%) | 1 |
| Tetracycline (230 vs 50)b | 148 (52.9%) | 112 (48.7%) | 36 (72%) | |
| Vancomycin (278 vs 49)b | 48 (14.3%) | 39 (13.6%) | 9 (18.4%) | 0.38 |
*oromaxillo-facial region and prosthetic device
aNot all agents listed tested in all isolates
bThe numbers in parentheses represent the total numbers of Staphylococcus aureus isolates performed susceptibility test
Abbreviations: BSIs Bloodstream infections, MRSA Methicillin-resistant Staphylococcus aureus, SA-BSI Staphylococcus aureus bloodstream infections
Comparison of outcome between monomicrobial SA-BSI and polymicrobial SA-BSI
| Prognostic indicators | Total | Mono-SA-BSI | Poly-SA-BSI | |
|---|---|---|---|---|
| Total Hospitalization days (M) (IQR) | 30 (17,54.5) | 28 (15,49) | 50 (21.25,85.75) | |
| Total ICU residence days (M) (IQR) | 1 (0,18) | 0 (0,12) | 23 (6.25,49.25) | |
| Cause sepsis | 288 (82.5%) | 249 (84.4%) | 39 (72.2%) | |
| Cause Septic shock (n,%) | 35 (10%) | 26 (8.8%) | 9 (16.7%) | 0.08 |
| 7 day total mortality rate (n,%) | 31 (8.9%) | 22 (7.5%) | 9 (16.7%) | |
| 14 day total mortality rate (n,%) | 46 (14.2%) | 33 (11.2%) | 13 (24.1%) | |
| 28 day total mortality rate (n,%) | 61 (17.5%) | 45 (15.3%) | 16 (29.6%) | |
| In-hospital mortality (n,%) | 71 (20.3%) | 54 (18.3%) | y (31.5%) |
Abbreviations: M Median, IQR Interquartile range, ICU Intensive care unit, SA-BSI Staphylococcus aureus bloodstream infections
Fig. 3Kaplan-Meier estimates of survival in patients with polymicrobial Staphylococcus aureus bloodstream infections and monomicrobial Staphylococcus aureus bloodstream infections. Abbreviations: SA-BSI, Staphylococcus aureus bloodstream infections